Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Colorectal Cancer

NCT05913570 is registered in ClinicalTrials.gov with LiuYing as lead sponsor.

NCT NCT05913570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05913570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Colorectal Cancer
Lead sponsor
LiuYing
Phase
Phase 2
Overall status
Unknown status
Start date
June 20, 2023
Completion date
December 20, 2023
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, microsatellite instability-high (msi-h), mismatch repair-deficient (dmmr), neoadjuvant therapy